| payload |
{"created_at":"2026-04-17T02:13:18.114 {"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:f09d5d622d4f9cc6","evidence_event_ids":["evt_ac050eb74221"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","company":"Tenaya Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_031810887d27ad1c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:42:50.871997+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt","source_event_id":"evt_ac050eb74221","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"d45c806fefd32476","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-16","2026-04-17","2026-05-27","2026-04-01","2026-12-31"],"entities":[{"asset_class":"equity","name":"Tenaya Therapeutics, Inc.","relevance":"high","symbol":"TNYA","type":"issuer"},{"asset_class":"unknown","name":"Faraz Ali, M.B.A.","relevance":"medium","symbol":"","type":"person"},{"asset_class":"unknown","name":"Deloitte & Touche LLP","relevance":"medium","symbol":"","type":"accounting_firm"},{"asset_class":"unknown","name":"proxydocs.com/TNYA","relevance":"low","symbol":"","type":"website"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal text (no prior filing/version details included).","The filing\u2019s full set of items (e.g., executive compensation, director biographies, voting procedures details beyond the excerpt) is not included in the provided text.","No explicit financial guidance/financial implications beyond the equity plan amendment share-reservation changes are stated in the provided excerpt."],"key_facts":["Form type: DEF 14A (proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934).","Annual meeting: Wednesday, May 27, 2026 at 8:00 a.m. Pacific Time.","Meeting format: virtual via live audio webcast.","Virtual access/voting: www.proxydocs.com/TNYA; stockholders can listen live, submit questions, and vote online using a control number from the proxy card.","Proxy statement mailing/internet availability: mailed on or about April 16, 2026; Notice of Internet Availability first sent or given on or about April 16, 2026.","Record date for stockholders of record: close of business on April 1, 2026.","Proposals to be voted on: (1) election of three Class II directors to hold office until the 2029 annual meeting; (2) ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026; (3) amendment and restatement of the 2021 Equity Incentive Plan to increase shares reserved for issuance by approximately 3% of outstanding shares and remove the annual limit of 4 million shares from the \u201cevergreen\u201d provision."],"numeric_claims":[{"label":"Annual meeting date/time","value":"May 27, 2026 at 8:00 a.m. Pacific Time"},{"label":"Virtual access site","value":"www.proxydocs.com/TNYA"},{"label":"Internet availability/mailing date","value":"on or about April 16, 2026"},{"label":"Stockholders of record date","value":"April 1, 2026 (close of business)"},{"label":"Number of directors to elect","value":"3 (Class II)"},{"label":"Director term end","value":"until 2029 annual meeting"},{"label":"Fiscal year end for auditor ratification","value":"December 31, 2026"},{"label":"Equity plan share increase","value":"approximately 3% of outstanding shares"},{"label":"Evergreen annual limit removed","value":"4 million shares"}],"primary_claim":"Tenaya Therapeutics, Inc. filed Form DEF 14A (proxy statement) on April 16, 2026 for its 2026 annual meeting on May 27, 2026.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Tenaya Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 annual meeting of stockholders. The filing discloses the meeting date/time, virtual format, record date, and the three proposals to be voted on.","topics":["SEC filing","proxy statement","annual meeting","corporate governance","director election","auditor ratification","equity incentive plan amendment"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Tenaya Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TNYA","tickers":["TNYA"],"title":"TNYA filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-158079.txt"}}... |